Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (7,036)	$ (5,389)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,119	1,816
Amortization of operating lease right-of-use assets	257	248
Amortization of intangible assets	2,155	2,155
Amortization of deferred financing costs and debt discount	112	116
Change in allowance for credit losses	(205)	24
Stock-based compensation expense	1,014	1,275
Loss on disposal of property and equipment	55	52
Loss on debt extinguishment	909	0
Changes in operating assets and liabilities:
Accounts receivable	(126)	(246)
Inventories	(344)	(1,616)
Prepaid expenses and other assets	388	(110)
Accounts payable	(268)	1,547
Accrued expenses and other liabilities	(611)	(267)
Deferred revenues	(165)	(472)
Operating lease liabilities	(279)	(236)
Net cash used in operating activities	(2,025)	(1,103)
Cash flows from investing activities:
Purchase of property and equipment	(3,166)	(2,037)
Cash paid in connection with TheraClear asset acquisition	0	(631)
Net cash used in investing activities	(3,166)	(2,668)
Cash flows from financing activities:
Proceeds from long-term debt	7,000	0
Payment of deferred financing costs	(97)	0
Payment of contingent consideration	(42)	0
Net cash provided by financing activities	6,861	0
Net increase (decrease) in cash, cash equivalents and restricted cash	1,670	(3,771)
Cash, cash equivalents and restricted cash, beginning of period	6,795	12,586
Cash, cash equivalents and restricted cash, end of period	8,465	8,815
Cash and cash equivalents	7,131	7,454
Restricted cash	1,334	1,361
Supplemental disclosure of cash flow information:
Cash paid for interest	917	523
Supplemental disclosure of non-cash operating, investing and financing activities:
Inventories acquired in connection with TheraClear asset acquisition	0	71
Intangible assets acquired in connection with TheraClear asset acquisition	0	10,182
Change in operating lease right-of-use assets and liability due to amended lease	0	446
Contingent consideration issued in connection with TheraClear asset acquisition	0	9,122
Common stock issued in connection with TheraClear asset acquisition	0	500
Modification of common stock warrants	384	0
Transfer of property and equipment to inventories	234	486
Change in intangible assets and fair value of contingent consideration	5,616	0
Accrued exit fee recorded as debt discount	$ 450	$ 0